CytomX Therapeutics CTMX Indefinite-Lived Research and Development Assets
Indefinite-Lived Research and Development Assets at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's indefinite-lived research and development assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's indefinite-lived research and development assets?
- CytomX Therapeutics (CTMX) reported indefinite-lived research and development assets of $401K in Q1 2026.
- How has CytomX Therapeutics's indefinite-lived research and development assets changed year-over-year?
- CytomX Therapeutics's indefinite-lived research and development assets decreased by 26.7% year-over-year, from $547K to $401K.
- What is the long-term trend for CytomX Therapeutics's indefinite-lived research and development assets?
- Over 5 years (2020 to 2025), CytomX Therapeutics's indefinite-lived research and development assets has grown at a -17.8% compound annual growth rate (CAGR), from $1.17M to $438K.